Regulus Therapeutics General and Administrative Expenses 2011-2026 | RGLS

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Regulus Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
14.7 M	9.96 M	9.83 M	10 M	8.81 M	11.3 M	12.9 M	17 M	18.4 M	19.1 M	11.5 M	7.43 M	4.93 M	-	3.92 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
19.1 M	3.92 M	11.4 M

Quarterly General and Administrative Expenses Regulus Therapeutics

2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
3.72 M	-	3.86 M	3.95 M	2.79 M	-	2.64 M	2.34 M	2.44 M	-	2.25 M	2.47 M	2.89 M	-	2.5 M	2.49 M	2.48 M	-	2.06 M	2.25 M	2.42 M	-	2.57 M	2.85 M	3.53 M	-	2.99 M	3.35 M	3.77 M	-	2.74 M	7.06 M	3.96 M	-	4.84 M	3.66 M	5.1 M	-	4.24 M	5.81 M	3.64 M	-	2.57 M	2.95 M	2.73 M	-	1.92 M	1.72 M	1.9 M	-	1.09 M	984 K	921 K	-	907 K	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
7.06 M	907 K	2.96 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	9.05 M	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Coherus BioSciences CHRS	101 M	$ 1.57	-3.68 %	$ 184 M	USA
Happiness Biotech Group Limited HAPP	2.31 M	-	1.35 %	$ 17.8 M	China
Amphastar Pharmaceuticals AMPH	85.9 M	$ 16.87	-2.49 %	$ 789 M	USA
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
AstraZeneca PLC AZN	19.9 B	-	-	$ 96.9 B	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Arcturus Therapeutics Holdings ARCT	46.1 M	$ 7.47	-4.6 %	$ 205 M	Israel
Athira Pharma ATHA	16.7 M	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	24.5 M	-	0.74 %	$ 768 M	Israel
Eton Pharmaceuticals ETON	35.8 M	$ 30.26	1.0 %	$ 814 M	USA
Galera Therapeutics GRTX	5.69 M	-	-32.59 %	$ 7.61 M	USA
Exelixis EXEL	519 M	$ 50.13	-1.9 %	$ 13.6 B	USA
Fortress Biotech FBIO	96.4 M	$ 2.41	4.78 %	$ 67.2 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Forte Biosciences FBRX	12.4 M	$ 23.11	-3.55 %	$ 299 M	USA
AbCellera Biologics ABCL	83.2 M	$ 4.09	-7.05 %	$ 1.22 B	Canada
Autolus Therapeutics plc AUTL	132 M	$ 1.63	2.52 %	$ 434 M	Britain
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
BioNTech SE BNTX	514 M	$ 89.55	-2.65 %	$ 21.6 B	Germany
Checkmate Pharmaceuticals CMPI	15.7 M	-	-	$ 231 M	USA
Galectin Therapeutics GALT	5.8 M	$ 2.17	-7.66 %	$ 139 M	USA
Celyad Oncology SA CYAD	10.5 M	-	-	$ 12.5 M	Belgium
Berkeley Lights BLI	95.1 M	-	-7.31 %	$ 87 M	USA
Generation Bio Co. GBIO	37.8 M	-	-	$ 344 M	USA
IMV IMV	17 M	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Gilead Sciences GILD	5.77 B	$ 129.58	-1.88 %	$ 161 B	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Can-Fite BioPharma Ltd. CANF	3.66 M	$ 3.36	-3.72 %	$ 5.53 M	Israel
Aeterna Zentaris AEZS	10.1 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Enlivex Therapeutics Ltd. ENLV	186 K	$ 0.72	-1.58 %	$ 32.9 M	Israel
Esperion Therapeutics ESPR	166 M	$ 3.12	-	$ 649 M	USA
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada
Genmab A/S GMAB	661 M	$ 26.54	-1.34 %	$ 1.72 B	Danmark
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	11 M	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	38.8 M	-	-	$ 28.6 M	USA